<h2 dir="ltr">HER2-low Cancers</h2>
HER2-low cancers refer to a subset of tumors that express low levels of the human epidermal growth factor receptor 2 (HER2), typically defined by an immunohistochemistry (IHC) score of 1+ or 2+ with negative in-situ hybridization (ISH) testing. Unlike HER2-positive cancers, which overexpress the HER2 protein and respond to HER2-targeted therapies like trastuzumab, HER2-low tumors were previously categorized as HER2-negative and lacked effective targeted treatment options.
<h2 dir="ltr">Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" aria-level="1">
Total targeted patient pool of selected indications for HER2-low cancers
</li>
<li dir="ltr" aria-level="1">
Treatment eligible pool of selected indications for HER2-low cancers
</li>
<li dir="ltr" aria-level="1">
Total incident cases of HER2-low breast cancers
</li>
<li dir="ltr" aria-level="1">
Age-specific cases of HER2-low breast cancers
</li>
<li dir="ltr" aria-level="1">
Stage-specific cases of HER2-low breast cancers
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/her2-low-cancers-epidemiology-forecast">HER2-low Cancers Epidemiology</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In the US, ovarian cancer had the lowest incidence in the HER2-low cancer pool.
</li>
<li dir="ltr" aria-level="1">
In 2024, the HER2-low breast cancer targeted pool was ~64K cases, expected to rise over the forecast period.
</li>
<li dir="ltr" aria-level="1">
The 60&ndash;69 age group accounted for ~30% of HER2-low breast cancer cases.
</li>
<li dir="ltr" aria-level="1">
In the EU4 and UK, Stage I breast cancer had the highest HER2-low cases in 2024, with ~31K cases.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/her2-low-cancers-market-forecast">HER2-low Cancers Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, the HER2-low cancer market in the 7MM was valued at USD 3.2 billion, with growth expected through 2034.
</li>
<li dir="ltr" aria-level="1">
Beyond breast cancer, gastric and biliary tract cancers show strong commercial potential for HER2-low therapies.
</li>
<li dir="ltr" aria-level="1">
The approval of ENHERTU for HER2-low breast cancer has doubled market sales, driven by its breakthrough efficacy in treating previously underserved metastatic cases.
</li>
</ul>
<h3 dir="ltr">HER2-low Cancers Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
The FDA approval of trastuzumab deruxtecan (Enhertu) for HER2‑low metastatic breast cancer&mdash;including DESTINY‑Breast04 data showing improved survival&mdash;has positioned this patient group as a distinct, targetable market segment&nbsp;
</li>
<li dir="ltr" aria-level="1">
The broader antibody‑drug conjugate (ADC) market has experienced an influx of clinical trials and development support. Accelerated FDA and EMA pathways, along with a surge in ADC-focused research, are bolstering confidence and investment in HER2‑low therapy innovation&nbsp;
</li>
</ul>
<h3 dir="ltr">HER2-low Cancers Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
ADC therapies like Enhertu are expensive, leading to access disparities, as seen when UK regulators rejected or limited coverage due to cost‐effectiveness concerns. Such reimbursement hurdles pose major obstacles ﹙NICE&rsquo;s non‑approval in England is a case in point﹚&nbsp;
</li>
<li dir="ltr" aria-level="1">
Limited data on long-term safety, emerging treatment resistance, and the complexity of managing adverse effects remain significant concerns with ADCs. For HER2‑low cancers, resistance and safety profiles are still being clarified, which may slow broader adoption.&nbsp;
</li>
</ul>
<h3 dir="ltr">HER2-low Cancers Key Therapies</h3>
<ul>
<li dir="ltr" aria-level="1">
DATROWAY (DATOPOTAMAB DERUXTECAN/DATO-DXD)
</li>
<li dir="ltr" aria-level="1">
TRODELVY (SACITUZUMAB GOVITECAN)
</li>
<li dir="ltr" aria-level="1">
DB-1303/BNT323 (TRASTUZUMAB PAMIRTECAN)
</li>
<li dir="ltr" aria-level="1">
AIDIXI (DISITAMAB VEDOTIN)
</li>
<li dir="ltr" aria-level="1">
EFTILAGIMOD ALPHA (IMP321)
</li>
<li dir="ltr" aria-level="1">
IFINATAMAB DERUXTECAN (I-DXD)/MK-2400
</li>
<li dir="ltr" aria-level="1">
BB-1701
</li>
<li dir="ltr" aria-level="1">
DF1001
</li>
<li dir="ltr" aria-level="1">
ZIIHERA (ZANIDATAMAB)
</li>
<li dir="ltr" aria-level="1">
HF158K1/HF-K1
</li>
<li dir="ltr" aria-level="1">
EMILTATUG LEDADOTIN (XMT-1660)
</li>
</ul>
And others.&nbsp;
<h3 dir="ltr">HER2-low Cancers Key Players</h3>
<ul>
<li dir="ltr" aria-level="1">
Daiichi Sankyo and AstraZeneca
</li>
<li dir="ltr" aria-level="1">
RemeGen and Pfizer (Seagen)
</li>
<li dir="ltr" aria-level="1">
Gilead Sciences
</li>
<li dir="ltr" aria-level="1">
Duality Biologics and BioNTech
</li>
<li dir="ltr" aria-level="1">
Immutep
</li>
<li dir="ltr" aria-level="1">
Merck
</li>
<li dir="ltr" aria-level="1">
Bliss Biopharmaceutical (Hangzhou)
</li>
<li dir="ltr" aria-level="1">
Zymeworks/Jazz Pharmaceuticals/ALX Oncology
</li>
<li dir="ltr" aria-level="1">
Dragonfly Therapeutics
</li>
</ul>
And others.

Her2 Low Cancers Market Infographic

Her2 Low Cancers Market

Her2 Low Cancers Market Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape